2-amino-9-[(2R,3R,4S,5R)-5-({[({[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]oxy}methyl)-3,4-dihydroxyoxolan-2-yl]-7-methyl-6-oxo-6,7-dihydro-3H-1,3,7,9$l^{5}-purin-9-ylium

• ChemBase ID: 1425
• Molecular Formular: C21H30N10O17P3+
• Molecular Mass: 787.440983
• Monoisotopic Mass: 787.10032444
• SMILES: Cn1c[n+]([C@@H]2O[C@H](CO[P@@](=O)(O)O[P@@](=O)(O)O[P@@](=O)(O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)n3cnc4c(N)ncnc34)[C@@H](O)[C@H]2O)c2c1c(=O)nc(N)[nH]2
• Canonical SMILES: Nc1nc(=O)c2c([nH]1)[n+](cn2C)[C@@H]1O[C@@H]([C@H]([C@H]1O)O)CO[P@](=O)(O[P@](=O)(O[P@](=O)(OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)n1cnc2c1ncnc2N)O)O)O
• InChI: InChI=1S/C21H29N10O17P3/c1-29-6-31(17-10(29)18(36)28-21(23)27-17)20-14(35)12(33)8(46-20)3-44-50(39,40)48-51(41,42)47-49(37,38)43-2-7-11(32)13(34)19(45-7)30-5-26-9-15(22)24-4-25-16(9)30/h4-8,11-14,19-20,32-35H,2-3H2,1H3,(H7-,22,23,24,25,27,28,36,37,38,39,40,41,42)/p+1/t7-,8-,11-,12-,13-,14-,19-,20-/m1/s1
• InChIKey: QQOHNVHGNZYSBP-XPWFQUROSA-O

NAMES AND DATABASE IDS

Names

• IUPAC name: 2-amino-9-[(2R,3R,4S,5R)-5-({[({[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)(hydroxy)phosphoryl]oxy}methyl)-3,4-dihydroxyoxolan-2-yl]-7-methyl-6-oxo-6,7-dihydro-3H-1,3,7,9$l^{5}-purin-9-ylium
• IUPAC Traditional name: GTA
• Brand Name: GTA; P1-7-METHYLGUANOSINE-P3-ADENOSINE-5',5'-TRIPHOSPHATE
• Synonyms: 7-Methyl-Gpppa

Database IDs

• PubChem SID: 160964885; 46507224
• PubChem CID: 446336

CALCULATED PROPERTIES

JChem

• Acid pKa: 0.8747506
• H Acceptors: 20
• H Donor: 10
• LogD (pH = 5.5): -13.873229
• LogD (pH = 7.4): -14.35106
• Log P: -11.6401
• Molar Refractivity: 161.4157 cm^3
• Polarizability: 63.88292 Å^3
• Polar Surface Area: 394.11 Å^2
• Rotatable Bonds: 12
• Lipinski's Rule of Five: false

ALOGPS 2.1

• Log P: -0.18
• LOG S: -2.45
• Solubility (Water): 2.89e+00 g/l

DETAILS

DrugBank - DB01649

Drug information: experimental